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Abstract
Acinetobacter baumannii is a major cause of healthcare-associated infection, often affecting critically ill patients. The purpose of the study was
to examine the associations of carbapenem resistance with mortality, length of hospital stay and hospital costs among patients infected with
A. baumannii in intensive-care units (ICUs) in Colombia. A prospective, multicentre cohort study was conducted among 165 patients with
A. baumannii infection admitted to ICUs between April 2006 and April 2010. Patients with carbapenem-resistant A. baumannii had higher
risk of 30-day mortality than patients with carbapenem-susceptible A. baumannii in the univariate analysis (unadjusted hazard ratio = 2.12;
95% CI 1.14–3.95; p 0.018). However, carbapenem resistance was not signiﬁcantly associated with risk of mortality (adjusted hazard
ratio = 1.45; 95% CI 0.74–2.87; p 0.28) after adjusting for APACHE II score and other confounding factors. We did not ﬁnd a signiﬁcant
difference in length of stay in ICU after the onset of infection between the two groups in the multivariate analysis (adjusted
mean = 13.1 days versus 10.5 days; p 0.14). The average total cost of hospitalization among patients with carbapenem-resistant
A. baumannii was signiﬁcantly higher than that among patients with carbapenem-susceptible A. baumannii in the multivariate analysis
(adjusted cost; US$ 11 359 versus US$ 7049; p <0.001). Carbapenem resistance was not signiﬁcantly associated with mortality, though we
are unable to rule out an increased risk due to the limited sample size. Carbapenem resistance was associated with an additional cost of
hospitalization.
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Introduction
Healthcare-associated infections are associated with an
increase in morbidity, mortality and healthcare costs. Acineto-
bacter baumannii is a major cause of healthcare-associated
infection, often affecting critically ill patients [1–3]. This
pathogen has become one of the most difﬁcult pathogens to
control and treat because of its prolonged survival and possibly
airborne transmission [3–5]. Moreover, multidrug-resistant
A. baumannii is rapidly emerging due to its capability to acquire
resistance to multiple classes of antimicrobials [6–9]. The rapid
increase and worldwide spread of carbapenem-resistant
A. baumannii infection is a major threat. Rates of carbapenem
resistance are generally higher in Latin America and Asia than in
North America and Europe [2]. In recent studies, rates of
resistance to carbapenem in A. baumannii infection ranged from
50% to 75% in Latin America [10,11].
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The health and economic impacts of carbapenem resistance
in patients with A. baumannii infection remain uncertain. There
is ongoing controversy regarding whether patients infected
with carbapenem-resistant A. baumannii (CRAB) are at greater
risk of mortality than patients infected with carbapenem-sus-
ceptible A. baumannii (CSAB). Previous studies from
North America, Europe and Asia have reported inconsistent
results regarding a potential association between carbapenem
resistance and mortality [12–24]. Furthermore, the literature
on the economic impact of carbapenem resistance is limited,
with a few studies suggesting that resistance may be associ-
ated with prolonged hospitalization and increased hospital
costs in patients with A. baumannii infection [9,14]. To our
knowledge, no study has examined the impact of carbapenem
resistance on clinical and economic outcomes in Latin
America.
The objective of this study was to examine the associations
of carbapenem resistance with mortality, length of hospital stay
and hospital costs among patients infected with A. baumannii in
intensive-care units (ICUs) in Colombia.
Methods
Study design and population
This prospective cohort study was conducted in the ICUs of
three tertiary-care hospitals in Bogota, Colombia. The ﬁrst
hospital consisted of 214 beds (17 of which were in the ICU),
the second one consisted of 398 beds (15 of which were in the
ICU), and the third one consisted of 275 beds (ten of which
were in the ICU). We included all adult patients diagnosed
with A. baumannii infection between 1 April 2006 and 1 April
2010. Patients were included in the study if they had been
hospitalized for more than 48 h. The study was approved by
the participating institutions and Universidad Nacional de
Colombia through their respective research ethics commit-
tees.
Microbiological examination
Microbiological and antimicrobial susceptibility of A. baumannii
was determined using microbiological cultures processed in
the microbiology laboratories using with automated systems.
Testing was carried out according to the methods recom-
mended by the CLSI [25]. The species were identiﬁed at
participating sites by the Vitek System (bioMerieux Vitek;
bioMerieux, Marcy l’Etoile, France) and MicroScan (Micro-
Scan Siemens; Siemens, Erlangen, Germany). Isolates identiﬁed
as intermediate or resistant to antibiotics were classiﬁed as
resistant to the agents. Carbapenem resistance was deﬁned as
resistance to imipenem or meropenem.
Data collection
We collected data regarding demographics, site of infection,
Acute Physiology and Chronic Health Evaluation (APACHE) II
score, comorbidities and the dates of hospital and ICU
admission. Patients were classiﬁed as having pneumonia
(ventilator-associated pneumonia and healthcare-associated
pneumonia), primary bacteraemia, central venous cathe-
ter-associated infection, surgical site infection, urinary tract
infection, skin and soft tissue infection and intra-abdominal
infection [26]. The number of diagnoses was deﬁned as the
total number of comorbidities and complications present on
the day of A. baumannii diagnosis [27]. We considered the
empirical antibiotic treatment appropriate if the patient
received at least one antibiotic to which the A. baumannii
isolated in vitro was susceptible. Additionally, such a drug had
to be administered within at least 72 h from the time of
culture collection.
Mortality was deﬁned as a death occurring within 30 days
after diagnosis of A. baumannii. The lengths of ICU and hospital
stay after infection were deﬁned as time from the day of
culture collection until discharge from the ICU or hospital, or
until death. We used an incidence-based approach to deter-
mine costs for individual patients (i.e. micro costing) during
their ICU stay. Costs were analysed from the perspective of a
third-party payer because hospitals are responsible for funding
infection control and quality improvement programmes. The
total cost of hospitalization included days of stay in the ICU,
fees for health professionals, surgical procedures, laboratory
tests, microbiological cultures and radiological examinations,
and antimicrobial therapy and other drugs used as a conse-
quence of the infection. The total cost of hospitalization for
each patient was obtained by multiplying the number of
resource units consumed by unit cost. Because the study was
conducted over 4 years, we adjusted costs to 2011 currency
using the Consumer Price Index for Colombia. We initially
measured costs in Colombian Pesos and then converted them
to US dollars.
Data analysis
To compare the characteristics of patients with CRAB versus
CSAB, we used the chi-squared test or Fisher’s exact test for
categorical variables, Student’s t-test for normally distributed
continuous variables and the Wilcoxon rank sum test for
non-normally distributed continuous variables. We employed
the Kaplan–Meier method to construct survival curves. We
used Cox proportional hazards models to investigate the
association between carbapenem resistance and risk of
mortality. The multivariate model was built using a backward
selection procedure. We ﬁrst considered variables with
p <0.05 in the univariate analysis as candidates for the
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multivariate model, then kept variables with p <0.05 and
previous known risk factors in the ﬁnal model.
To examine the associations of carbapenem resistance with
the length of hospital stay and cost of hospitalization, we
employed generalized linear models with a c distribution and a
log link function. Univariate and multivariate analyses were
conducted. We estimated predicted lengths of stay and cost
based on average marginal effects from a generalized linear
model. Non-parametric bootstrap estimation was used to
construct 95% CI and p-values. All statistical analyses were
conducted using SAS version 9.2 (SAS Institute, Cary, NC,
USA).
Results
The cohort comprised a total of 165 patients, the majority of
which were male (64%) and had CRAB infection (63%). The
average age (SD) was 50 years (19 years) and the average
APACHE II score at onset of infection was 13 (6). Compared
with patients with CSAB, patients with CRAB had higher
APACHE II scores at onset of infection and lower albumin
levels (p <0.01 and p 0.04, respectively; Table 1). Patients with
CRAB were more likely to receive inappropriate empirical
antibiotic treatment than patients with CSAB (38.5% versus
16.4%; p 0.003).
Within 30 days of the onset of infection, 55 patients died
(33%). Patients with CRAB had signiﬁcantly higher risk of
TABLE 1. Baseline characteristics comparing patients with carbapenem-resistant Acinetobacter baumannii and patients with
carbapenem-susceptible A. baumannii (n = 165)
Baseline characteristics Carbapenem-resistant (n = 104)a Carbapenem-susceptible (n = 61)a pb
Age 51.2  19.4 47.7  19.0 0.006
Gender, male 63 (60.6%) 42 (68.9%) 0.29
APACHE II score
At admission to ICU 12.8  5.4 10.1  4.6 0.001
At onset of infection 14.2  6.2 11.6  5.2 0.006
Number of diagnoses
<5 62 (59.6%) 39 (63.9%) 0.58
≥5 42 (40.4%) 22 (36.1%)
White blood cell count at onset of infection (/mm3) 17 800  6100 19 300  5800 0.14
Albumin (mg/dL) 2.93  0.78 3.20  0.78 0.038
Acute respiratory distress syndrome 38 (36.5%) 25 (41.0%) 0.57
Length of hospital stay before infection (days) 20.2  23.5 16.8  14.5 0.44
Length of ICU stay before infection (days) 10.3  8.3 10.1  10.1 0.43
Inappropriate empirical antimicrobial treatment 40 (38.5%) 10 (16.4%) 0.003
Site of infection
Pneumonia 30 (28.9%) 27 (44.3%) 0.044
Bacteraemia 14 (13.5%) 10 (16.5%) 0.61
Central venous catheter-associated infection 13 (12.5%) 7 (11.5%) 0.85
Surgical infection 28 (26.9%) 12 (19.7%) 0.29
Urinary tract 10 (9.6%) 1 (1.6%) 0.06
Soft tissue 4 (3.9%) 3 (4.9%) 0.71
Intra-abdominal 5 (4.8%) 1 (1.6%) 0.41
Primary and secondary bacteraemia 30 (28.9%) 17 (27.8%) 0.89
Diagnostic category
Elective surgery 10 (9.6%) 7 (11.5%) 0.70
Emergency surgery 24 (23.1%) 21 (34.4%) 0.11
Medical 54 (51.9%) 20 (32.8%) 0.017
Trauma 16 (15.4%) 13 (21.3%) 0.33
Comorbidities
Diabetes 7 (6.8%) 3 (4.9%) 0.75
Hypertension 17 (16.5%) 12 (19.7%) 0.38
Chronic obstructive pulmonary disease 12 (11.7%) 10 (16.4%) 0.59
Neoplasia 1 (1.0%) 1 (1.6%) 1.0
Renal insufﬁciency 1 (1.0%) 0 (0%) 1.0
APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive-care unit.
aMean  SD or n (%).
bChi-squared or Fisher’s exact test was used for categorical variables. Student’s t-test was used for continuous variables. However, for lengths of hospital and ICU stays, we used
Wilcoxon rank sums test.
FIG. 1. Risk of 30-day mortality comparing patients with carbape-
nem-resistant Acinetobacter baumannii and patients with carbape-
nem-susceptible A. baumannii (log rank test, p 0.02).
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30-day mortality than patients with CSAB in the univariate
analysis (40% versus 21%; unadjusted hazard ratio (HR) = 2.12;
95% CI 1.14–3.95; p <0.05; Fig. 1 and Table 2). However, after
adjusting for age, gender, APACHE II score, number of
diagnoses and inappropriate empirical antimicrobial treatment
in the multivariate model, carbapenem resistance was not
signiﬁcantly associated with risk of mortality (adjusted
HR = 1.45; 95% CI 0.74–2.87; p 0.28).
TABLE 3. Length of hospital and intensive-care unit stays comparing patients with carbapenem-resistant Acinetobacter
baumannii and patients with carbapenem-susceptible A. baumannii
Length of stay after infection
Unadjusted Adjusteda
Carbapenem-resistant,
Mean  SD
Carbapenem-susceptible,
Mean  SD pb
Carbapenem-resistant,
Mean (95% CI)
Carbapenem-susceptible,
Mean (95% CI) p
Hospital days 19.0  17.2 16.2  18.0 0.20 19.3 (16.0, 22.5) 16.2 (11.5, 19.9) 0.58
Intensive-care unit days 13.2  13.8 10.1  8.7 0.04 13.1 (10.8, 15.4) 10.5 (8.2, 12.8) 0.14
aPredicted lengths of stay based on average marginal effects from a generalized linear model with a log link function and c distribution that adjusted for age, gender, APACHE II
score and site of infection. 95% CIs and p-values were estimated by non-parametric bootstrapping.
bBased on Wilcoxon rank sums test.
TABLE 2. Carbapenem-resistance and other risk factors associated with 30-day mortality among patients infected with
Acinetobacter baumannii
Risk factors n/Na
Unadjusted HR
(95% CI)b p
Adjusted HR
(95% CI)b p
Carbapenem
Resistant 42/104 2.12 (1.14–3.95) 0.018 1.45 (0.74–2.87) 0.28
Susceptible 13/61 1.0 1.0
Age
<65 years 34/123 1.0 1.0
≥65 years 21/42 2.27 (1.32–3.92) 0.003 1.89 (1.07–3.35) 0.03
Gender
Male 31/105 1.0 1.0
Female 24/60 1.49 (0.87–2.53) 0.14 1.56 (0.88–2.76) 0.13
APACHE II
<10 2/52 1.0 1.0
10–19
23/77 9.12 (2.15–38.68) 0.003 9.32 (2.19–39.70) 0.003
≥20 30/36 38.37 (9.12–161.31) <0.001 23.06 (5.31–100.16) <0.001
Number of diagnoses
<5 19/101 1.0 1.0
≥5 36/64 3.60 (2.06–6.29) <0.001 2.22 (1.18–4.18) 0.01
Empirical antimicrobial treatment
Inappropriate 21/50 1.48 (0.86–2.56) 0.15 1.39 (0.78–2.46) 0.26
Appropriate 34/115 1.0 1.0
Length of hospital stay before infection
<10 days 14/48 1.0 –
10–19 days 23/67 1.13 (0.59–2.16) 0.72
≥20 days 17/48 1.12 (0.56–2.24) 0.75
Length of ICU stays before infection
<10 days 33/108 1.0 –
≥10 days 22/57 1.25 (0.73–2.15) 0.41
Albumin
≥2.5 mg/dL 37/125 1.0 –
<2.5 mg/dL 17/39 1.67 (0.94–2.96) 0.08
Acute respiratory distress syndrome
Presence 19/63 0.90 (0.52–1.56) 0.70 –
Absence 36/102 1.0
Primary and secondary bacteraemia
Presence 16/47 1.07 (0.60–1.92) 0.81
Absence 39/118 1.0
Site of infection
Pneumonia 17/57 1.0 –
Bacteraemia 8/24 1.15 (0.50–2.67) 0.74
Catheter-associated 7/20 1.15 (0.48–2.78) 0.75
Surgery infection 14/40 1.11 (0.55–2.26) 0.77
Urinary tract 7/11 2.36 (0.98–5.69) 0.06
Soft tissue or skin 1/7 0.40 (0.05–2.99) 0.37
Intra-abdominal 1/6 0.52 (0.07–3.89) 0.52
Diagnostic category
Emergency surgery 12/45 1.00 –
Elective surgery 7/17 1.73 (0.68–4.39) 0.25
Medical 28/74 1.45 (0.74–2.85) 0.28
Trauma 8/29 0.99 (0.40–2.41) 0.97
APACHE II, Acute Physiology and Chronic Health Evaluation II; HR, hazard ratio; ICU, intensive-care unit.
aNumber who died (n) / Number at risk (N).
bUnadjusted and adjusted hazard ratios and 95% CIs were estimated from Cox proportional hazards model.
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Patients with CRAB had longer ICU stays after the onset of
infection than patients with CSAB in the univariate analysis
(mean = 13.2 days versus 10.1 days; p 0.04; Table 3). How-
ever, the association was attenuated in the multivariate model
(adjusted mean = 13.1 days versus 10.5 days; p 0.14). We did
not ﬁnd a signiﬁcant difference in length of hospital stay after
infection between the two groups (adjusted mean = 19.3 days
versus 16.2 days; p 0.58).
The average total cost of hospitalization among patients with
CRAB was signiﬁcantly higher than that among patients with
CSAB in both the univariate and multivariate analyses (adjusted
US$ 11 359 versus US$ 7049; p <0.01; Table 4). Carbapenem
resistance was associated with an additional treatment cost of
US$ 4309 (95% CI US$ 2819–5645; p <0.01) after adjusting for
age, gender, APACHE II score and site of infection. Patients
with CRAB had signiﬁcantly higher costs for hospital-related
cost and for cost of antimicrobial drugs than patients with CSAB
(both p <0.01 and p <0.01).
Discussion
In this prospective cohort study of patients with A. baumannii
infection in Colombia, we found that carbapenem resistance
was not signiﬁcantly associated with risk of 30-day mortality
after adjusting for severity of illness and other confounding
factors. Our study demonstrated that the average total cost of
hospitalization among patients infected with CRAB was
signiﬁcantly higher than that among patients infected with
CSAB in the multivariate analysis.
Patients infected with CRAB are more likely to have severe
illness and less likely to receive appropriate empirical antibiotic
treatment than patients infected with CSAB. Therefore, in the
unadjusted analysis, the higher mortality rate in patients with
CRAB compared with patients with CSABmay be partly a result
of the severe underlying disease status of patients with CRAB.
Though the adjusted HR was attenuated and not statistically
signiﬁcant, it is possible that carbapenem resistance may have
contributed to an increased risk of mortality; however, our
study may not have enough statistical power to detect a
statistically signiﬁcant association. Previous studies have
reported conﬂicting results as to whether high risk of death
in patients with CRAB is the result of carbapenem resistance or
greater severity of underlying illness [12–24]. Among 13
previous studies of patients with A. baumannii infection, ﬁve
studies found that carbapenem resistance may increase risk of
mortality after adjusting for severity of illness and other
confounding factors [13–17]. However, other studies did not
ﬁnd statistically signiﬁcant association in the multivariate
analysis and reported that higher crude mortality rates in
patients with CRAB were due to severity of illness, inappro-
priate antimicrobial therapy or primary source of infection [18–
24]. Most studies had a limited sample size. It is also important
to note substantial differences in the methodology, rates of
carbapenem resistance, study population and study country,
which may have resulted in conﬂicting ﬁndings. Furthermore,
previous studies have mostly examined patients with bactera-
emia who may be at greater risk of resistant infection.
We demonstrated that carbapenem resistance was signif-
icantly associated with higher average cost of hospitalization
(adjusted cost for CRAB US$ 11 359 versus CSAB US
$ 7049). Longer ICU stays and higher costs from antimicrobial
drugs have contributed to the higher cost in patients with
CRAB. Similarly, Lautenbach et al. [14] found that patients with
CRAB compared with patients with CSAB have higher hospital
charges in the USA (US$ 33 4516 versus US$ 276 059;
p 0.03). Lee et al. [9] also found that average costs for patients
infected with multidrug-resistant A. baumannii were higher
than those of patients infected with non-multidrug-resistant
A. baumannii in Taiwan (US$ 9349 versus US$ 4863; p <0.05).
Researchers have also found that antimicrobial resistance is
associated with higher hospital costs in other gram-negative
bacterial infections, such as Pseudomonas aeruginosa [28,29].
Our study has several notable strengths. The present study
is the ﬁrst in Latin America to examine the clinical and
economic impacts of carbapenem resistance among patients
TABLE 4. Cost of hospitalization (US$) comparing patients with carbapenem-resistant Acinetobacter baumannii and patients
with carbapenem-susceptible A. baumannii
Cost (US$)
Unadjusted Adjusteda
Carbapenem
-resistant,
Mean  SD
Carbapenem-susceptible,
Mean  SD pb
Carbapenem-resistant,
Mean (95% CI)
Carbapenem-susceptible,
Mean (95% CI)
Mean difference
(95% CI) p
Total cost 11 822  7334 7178  3938 <0.001 11 359 (10 053–12 483) 7049 (6206–8021) 4309 (2819–5645) <0.001
Hospital-related cost 7726  4458 4704  3287 <0.001 7596 (6736–8440) 4539 (3824–5291) 3057 (1943–4134) <0.001
Cost of antimicrobials 4096  4026 2475  2042 0.002 3657 (3069–4159) 2520 (2009–3073) 1137 (386–1894) 0.002
aPredicted cost based on average marginal effects from a generalized linear model with a log link function and gamma distribution that adjusted for age, gender, APACHE II score,
and site of infection. 95% CIs and p-values were estimated by non-parametric bootstrapping.
bp-value based on Wilcoxon rank sums test.
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with A. baumannii infection. Furthermore, we prospectively
collected clinical and cost data, which are not typically collected
systematically in Colombia. We also carefully collected and
adjusted for a number of important confounding factors.
Several limitations are worth noting. Although we adjusted
for many known risk factors for outcomes, as with any
observational study, it is difﬁcult to infer causation because of
possible unmeasured factors, including hospital or individual
level characteristics. Carbapenem resistance in A. baumannii
may result from a number of mechanisms, including production
of b-lactamases, over-expression of efﬂux pump, alterations in
outer membrane proteins, or penicillin-binding protein mod-
iﬁcations [30]. We did not conduct molecular level analysis to
characterize mechanisms of carbapenem resistance. Another
limitation is that our study may not have sufﬁcient statistical
power to detect a statistically signiﬁcant difference in the
mortality rate. Combining results from previous studies using
meta-analysis techniques may further elucidate whether such
an association exists.
In conclusion, we observed a high rate of carbapenem
resistance (63%) in patients with A. baumannii infection admitted
to the ICU. Carbapenem resistance was not signiﬁcantly asso-
ciatedwith risk of 30-daymortality, thoughwe are unable to rule
out an increased risk due to the limited sample size. Our study
demonstrated that A. baumannii infection leads to substantial
hospital costs, with carbapenem resistance adding additional
costs. In addition to prevention and control of healthcare-asso-
ciated infections, timely and appropriate antimicrobial treatment
is critical for patients with A. baumannii infection, particularly
those infected by carbapenem-resistant strains.
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